Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study

OBJECTIVE: Current prevention and/or treatment options for respiratory syncytial virus (RSV) infections are limited as no vaccine is available. Prophylaxis with palivizumab is very expensive and requires multiple intramuscular injections over the RSV season. Here we present proof-of-concept data usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajapaksa, Anushi E., Do, Lien Anh Ha, Suryawijaya Ong, Darren, Sourial, Magdy, Veysey, Duncan, Beare, Richard, Hughes, William, Yang, William, Bischof, Robert J., McDonnell, Amarin, Eu, Peter, Yeo, Leslie Y., Licciardi, Paul V., Mulholland, Edward K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466567/
https://www.ncbi.nlm.nih.gov/pubmed/32973520
http://dx.doi.org/10.3389/fphar.2020.01291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466567/
https://www.ncbi.nlm.nih.gov/pubmed/32973520
http://dx.doi.org/10.3389/fphar.2020.01291

Ejemplares similares